Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Saturday morning. The firm issued a hold rating on the stock.

ONCT has been the subject of a number of other reports. Northland Capmk lowered Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Securities restated a “market perform” rating and set a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

Oncternal Therapeutics Price Performance

NASDAQ:ONCT opened at $0.53 on Friday. Oncternal Therapeutics has a one year low of $0.53 and a one year high of $13.14. The company has a market cap of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The firm has a 50-day moving average of $1.06 and a 200-day moving average of $3.72.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.